Ron Allen appointed as eFront’s Chief Client Success Officer
Paris and New York, August 13, 2019 – eFront, the world’s leading technology solution for alternative investment management, announced today the …
Tokyo | February 8, 2019 – eFront, the world’s leading alternative investment management software and solutions provider, announced today that Axil Capital, a life sciences focused venture capital firm based in Tokyo, has adopted eFront’s software solution for managing its entire private equity investment cycle.
Axil Capital will benefit from eFront Invest GP’s suite of automated fund management tools encompassing intuitive accounting, advanced reporting and streamlined workflows within a centralized industry-leading solution. eFront Invest GP has now been adopted by more than 500 general partners and asset servicers worldwide.
Fred Shane, Managing Partner at Axil Capital said, “We chose eFront because it offers the most comprehensive solution for venture capital and private equity firms, encompassing all aspects of the investment life cycle. Adoption of eFront Invest GP will allow us to process large volumes of data, quickly and accurately, without increasing our internal resources. We were particularly attracted to eFront’s combination of ready-made template solutions that can be further customized to address our specific needs.”
John Legrand, Managing Director Asia-Pacific at eFront added, “Axil Capital’s adoption of eFront Invest GP is a further endorsement of eFront’s leading position in Asia-Pacific markets, including Japan. We look forward to working with Axil and supporting their core business.”
Axil Capital was spun out of Mizuho Securities in 2017, with early investors that include Mizuho, the Japanese government, a global pharma, and a small group of visionary investors from inside and outside of Japan. Its goal is to create synergies between the biotech ecosystem in Japan and the rest of the world, resulting in great companies and great returns for their investors. With one fund and 40M in assets under management, Axil focuses on innovation in biotechnology.